Phesi launches Patient Access Score for clinical trial sponsors to enhance investigator selection and accelerate patient recruitment

Phesi launches Patient Access Score for clinical trial sponsors to enhance investigator selection and accelerate patient recruitment  

Latest real-world metric in Phesi’s Trial Accelerator™ highlights where trial execution fails at a site level, giving planners a patient-centred view of design and execution for leading assets  

Boston, USA, November 7, 2023: Phesi, a global provider of patient-centric data analytics has enhanced its Trial Accelerator™ platform with the addition of the Patient Access Score (PAS), to enable clinical trial sponsors to identify the most effective investigators. The PAS metric derives from the Phesi Digital Patient Profile (DPP); using real-world data from more than 95 million patients and over 500,000 clinical studies from Phesi’s Trial Accelerator™ platform.  PAS can be applied to improve investigator and site selection, reduce protocol amendments, and save costs by eliminating activation of non-performing sites. 

“For too long, the clinical development industry has accepted and absorbed the financial burden of unnecessary protocol amendments and poorly performing sites. These often-excessive costs and the significant impact on time to market no longer have to be part of life,” said Dr Gen Li, President and Founder of Phesi. “By using contextualized data for precise site and investigator selection, unnecessary protocol amendments and CRO change orders can be zeroed completely. We know that poorly performing sites are up to ten times more expensive than those operated by the best-performing investigators, as measured by cost-per-data points collected from patients. The Patient Access Score will accelerate patient recruitment and eliminate non-recruiting sites – which is not only critical for sponsors in these economically challenging times, but also lessens the burden on patients.”  

PAS is an extension of Phesi’s existing scoring and performance toolkit that enables precision in patient-centric trial design – providing detailed insights into the number of patients an investigator can potentially reach alongside their historical clinical trial experience.  For the first time, PAS bridges data between investigator sites and targeted patient population. This ensures study design is optimized to meet commercial objectives and that development programs are patient-centric. 

Specifically, PAS measures the probability of an investigator site to access patient population as being defined in the protocol. By focusing on investigators from Trial  Accelerator who contributed patients to those we used to construct a specific DPP. The more cohorts of patients in a DPP a particular investigator is associated with, the higher probability that investigator site will be able to recruit patients aligned with the protocol design. PAS adds on to a set of investigator site performance measures to further enhance the predictability of Trial Accelerator to patient enrollment in clinical trials.

PAS is applicable in all indications but particularly for rare diseases where few patients are available, as well as non-rare but complex conditions with several comorbidities or a broad range of patient characteristics. For example, despite stroke being the second biggest killer globally, the variation in types of stroke and in each patient cohort makes it difficult to study. Identifying an investigator experienced with the type of stroke under study (i.e., transient ischemic attack, ischemic or hemorrhagic stroke), who also has access to patients in the acute phase of stroke and with the ability to enroll those patients rapidly, is highly challenging.  

“I have spent the better part of 3 decades working on ways to validate sites’ enrollment potential,” explained Beth Harper, President, Clinical  Performance Partners, Inc.   “Gen and his team at Phesi have finally cracked the code on how to do this in an evidence-based, efficient and effective manner.  The industry can finally say goodbye to traditional feasibility questionnaires and hello to predictive site performance.” 

Phesi’s Trial Accelerator uses real-world, current data, so no inactive investigators or sites are recommended. By generating a specific contextualised score via PAS, sponsors can activate, enroll and get quality data quickly. 

Find out more about Phesi’s Trial Accelerator and Digital Patient Profiles here.